The House of Kolor Sunrise Pearl-painted machine is a modern-era throwback to manufacturers’ “futuristic” concept cars, and ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...

(Reuters) -Alliance Laundry is targeting a valuation of up to $4.34 billion in its U.S. initial public offering, the commercial laundry equipment maker said on Monday, as the frenzy around first-time ...

PARKLAND, Fla. — Parkland’s Marjory Stoneman Douglas High School was “placed on secure status as a precautionary measure after law enforcement received a tip about a possible weapon on campus” on ...

MSD said it is looking forward to further evaluating EVX-B3 as part of its early vaccine pipeline. Credit: Iryna Imago via Shutterstock.com. Merck & Co (MSD) has taken the first of two possible ...

Merck (MSD) has received approval from the US Food and Drug Administration (FDA) for the subcutaneous format of its best-selling oncology asset, Keytruda. Image credit: U.P.SD via ShutterStock.com.

MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 MSD will assume full responsibility for the further ...

Danish clinical-stage techbio Evaxion Biotech (Nasdaq: EVAX) saw its shares leap nearly 26% to $4.15 on the news it has out-licensed its vaccine candidate EVX-B3 to MSD (trading name of Merck & Co ...

Abstract: By quantizing weights with different precision for different parts of a network, mixed-precision quantization promises to reduce the hardware cost and improve the speed of deep neural ...